Governor Wolf Renews Opioid Disaster Declaration, Notes Recent Progress

first_img Human Services,  Press Release,  Public Health,  Substance Use Disorder Harrisburg, PA – Governor Tom Wolf today signed the fourth renewal of his 90-day opioid disaster declaration and noted recent successes in the ongoing fight against the epidemic.“I am again renewing the 90-day opioid disaster declaration, the best current means we have to maintain a concerted effort focused on fighting this scourge on our state and our nation,” Gov. Wolf said. “The renewal allows the 16 state agencies working together as part of the Opioid Command Center at PEMA to continue their collaborative approach at creating and implementing initiatives that are making a difference across many areas of this battle.”The American Medical Association earlier this week hailed Pennsylvania’s fight against opioids as a model for the rest of the country.Last week, Pennsylvania distributed more than 6,000 free naloxone kits as part of Stop Overdoses in PA: Get Help Now Week across the commonwealth.“With 80 public health centers participating in the naloxone giveaway, thousands of Pennsylvanians now have a chance to save a life and, in effect, be part of our first responder network,” Gov. Wolf said. “EMS and law enforcement alone have reversed nearly 20,000 overdoses this past year, getting 92 percent of those revived to a health care facility and into treatment.”The disaster declaration, which was introduced in January, and renewed in April, June and September, was set to expire this month. The renewal allows for the initiatives introduced in the past eleven months to continue without interruption.The governor detailed progress with additional initiatives introduced as part of the disaster declaration:Implemented more than 45 treatment centers (Centers of Excellence) across the commonwealth that to date have provided a level-of-care assessment for substance use disorder to more than 12,000 individuals.Expanded Medicaid to more Pennsylvanians, which now covers substance use disorder care for over 125,000 Pennsylvanians.Secured more than $110 million in federal grants to support prevention, treatment such as medication-assisted treatment, recovery, career services, and other programs to aid in fighting this crisis.Strengthened the use of the Prescription Drug Monitoring Program (PDMP), which enables health care providers to safely prescribe controlled substances to their patients. More than 90,000 registrants are conducting more than 1.6 million patient searches each month. Since PDMP implementation, opioid prescribing has decreased by 24 percent.Introduced a suspicious activity prescribing tool with Attorney General Josh Shapiro to aid in reducing illegally prescribing controlled substances and identifying people who may need to be guided to treatment for substance use disorder.Announced improved prescribing guidelines for the safe and effective use of opioids, including in sports medicine, for minors, and Pennsylvanians on Medicaid, as well as improved education for medical professionals on opioid prescribing.Launched a 24/7 helpline, 1-800-662-HELP, for those who need immediate assistance with drug and alcohol problems. More than 36,000 Pennsylvanians have contacted the statewide helpline for assistance.Signed legislation to support grandparents raising grandchildren as a result of the opioid crisis.Hosted more than 100 opioid roundtables across the state to engage first responders, treatment providers, families, and non-profit organizations to listen and learn about local community needs and what the state can do to help.“It is critical that we keep building on our efforts at prevention, rescue, and treatment by extending the disaster declaration for another 90 days and urging the General Assembly to again take up a public health emergency when they return,” Gov. Wolf said. “We must work to ensure that my administration and local partners can continue to use every tool available to them to help people and communities in need.”More information on the Wolf Administration’s efforts to combat the opioid epidemic and how people suffering from this disease can get help is here. SHARE Email Facebook Twitter December 21, 2018center_img Governor Wolf Renews Opioid Disaster Declaration, Notes Recent Progresslast_img read more

FB : Regroup: SU offense shows need for improvement off shaky spring

first_img Published on April 18, 2011 at 12:00 pm Doug Marrone had a clear objective in mind Saturday in the Carrier Dome.‘Again, our thought is to put a game out there,’ Marrone said to a crowd of reporters in the Dome end zone. ‘It’s what a lot of people wanted. It’s what I wanted as a coach. It’s what us coaches wanted. I think it is what our players wanted. The level of competition definitely increased in their mind.’Analyzing that increased competition 15 yards behind the line of scrimmage, SU’s head coach Marrone scrutinized 16 more plays than he did last year in SU’s annual Spring Game. Of the 104 total plays, his offense scored one touchdown. Of the 88 plays last year, his offense scored four touchdowns.In terms of points, a drop-off occurred — even if the offense returns nine starters for 11 spots from last season’s Pinstripe Bowl-winning team.A real game is what it was billed as and what it became for the SU players. The White team, led by defensive coordinator Scott Shafer, defeated the Blue team, led by offensive coordinator Nathaniel Hackett, 13-7. Two teams lined up opposite each other, defensive players alongside offensive players on each sideline. The same did not occur last year, as the SU offense defeated the defense 66-58 in a special scrimmage scenario.AdvertisementThis is placeholder textBut for Marrone, Saturday was merely the continuation of spring practice — even if 4,206 fans attended the game. Removed from his head coach’s headset, he stood in the same spot he does for every spring practice. It was the same stoic stance SU fans fell in love with through the past year since the Orange’s 2010 Spring Game.And Marrone displayed the same body language as he did when seeing the SU defense outplay the Orange offense for the majority of practices in the last month and a half. With the end of Syracuse’s 2011 spring practice, questions are still plentiful for the Orange offense. And those questions are there for the simple fact that a Syracuse defense — one that returned much less than the Orange offense — ended spring as the more polished and successful unit.The single touchdown scored by two Syracuse offenses validated that. Even if returning SU starting quarterback Ryan Nassib feels his offense has made clear strides this spring.‘I think me and the receivers are starting to have really good chemistry,’ he said. ‘We were starting to throw the ball without them looking, and they would be there to make the plays.’Mental errors may have decreased substantially, but still, offensive success was rare to come by this spring. Points especially.The stars of the spring were supposed to be offensive. SU returned four of five offensive linemen. Its four best pass-catching threats all returned in wide receivers Marcus Sales, Alec Lemon and tight end Nick Provo. Van Chew returns as well, but he missed most of the practices and the Spring Game due to injury. Nassib began his third consecutive spring as SU’s starter. And Antwon Bailey was finally given the opportunity to be the feature back with Delone Carter gone, after splitting reps with him the past two seasons.On the other side of the ball, one starter in Phillip Thomas returned in the secondary, while another, Shamarko Thomas, was hurt. Marquis Spruill returned in the linebacking corps, but moved from outside to middle linebacker. And the interior of the defensive line was gutted.But practice after practice — whether in Rochester, N.Y., or inside the Dome or Manley Field House — the defense won out more often than not. Thomas vocally led a hard-hitting defense that fostered the positive surprises of the spring. Freshman linebacker Dyshawn Davis was another surprise, as well as the mature and clutch play of linebacker Dan Vaughan — who played like a deserving starter this spring after once being thought of as a forever benchwarmer.But Saturday, in the context of a real game, Vaughan and his bruising hits led the defense in a resounding victory. Yes, the defense won, even if this was the kind of ‘game’ Marrone wanted to supply for fans.And with the defense’s successes against the offense, the questions not only still linger for the offense, but are amplified. The reason for that? In the 2010 Spring Game, the offense defeated the defense 66-58, despite the fact that Marrone and Hackett’s offense had only been implemented for a month. In 2010, Carter was suspended from playing, and Nassib and Bailey were a year younger.But Marrone, Hackett, Bailey and Nassib aren’t reading into Saturday’s lack of offense at all. There were two reasons for that. One: Nassib and Bailey each looked solid, as the quarterback threw for 227 yards while maintaining a presence in the pocket and the running back ran for 118 yards and a touchdown on 20 carries. Two: The offensive line wasn’t together. The unit was scattered among the White and Blue squads.‘The O-line is a different case, ‘cause they really perform as a unit,’ Nassib said. ‘So when you split them up, it is a little bit different. We knew that was an issue going in.’It became a glaring issue, as three of SU’s starting offensive linemen failed to lead the Blue team to a single score, albeit with a backup quarterback and running back.By the end of the game, and the spring, the offense hasn’t taken the step forward it hoped it would.This was supposed to be the spring where the offense took off. This was supposed to be the spring where touchdowns were scored. This was supposed to be the spring where the offense was better than the defense.Instead, this was an OK month for the offense. Just OK. And even though Hackett was content with it, he realized there is still much work to do before Wake Forest comes to the Dome on Sept. 3.Points need to be scored.‘That is the story, and that is the way it was last year, and we have got to get out of that,’ Hackett said. ‘That is the No. 1 thing. That is the No. 1 challenge. We have got to make points, and that is about touchdowns and not field goals.’Tony Olivero is the development editor at The Daily Orange, where his column appears occasionally. He can be reached at Commentscenter_img Facebook Twitter Google+last_img read more

Exenatide treatment improves depression symptoms in PD patients

first_imgAug 1 2018Non-motor symptoms of Parkinson’s disease (PD), such as depression, apathy, cognitive impairment, sleep disorders, and sensory symptoms, can have a greater impact on health-related quality of life than motor deficits. In a post hoc analysis of the exenatide-PD trial results, investigators found that patients on exenatide treatment experienced improvements in severity of depression, independent of whether their motor function improved. They report their findings in the Journal of Parkinson’s Disease.GLP-1 receptor agonists are used to treat people with type 2 diabetes by stimulating the GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain and may also play a role to in the treatment of PD. In the exenatide-PD trial, a randomized, placebo-controlled clinical trial in patients with moderate-stage PD, the GLP-1 receptor agonist exenatide showed positive effects on the motor severity of the disease, which continued 12 weeks beyond the period of exenatide exposure.”In the original analysis of the exenatide-PD trial, the primary outcome was a comparison in the motor severity of PD,” explained Thomas Foltynie, PhD, MBBS, Sobell Department of Motor Neuroscience, UCL Institute of Neurology, and The National Hospital for Neurology and Neurosurgery, London, UK, who led the exenatide trial and is lead investigator of the current study. “Analysis of pre-defined secondary outcomes revealed no statistically significant differences between patients treated with exenatide in total non-motor symptom burden and overall quality of life measures, including the Non Motor Symptoms Scale (NMSS). However, the response of individual non-motor symptoms to an intervention may vary.”The current research was a post hoc analysis of the trial data and aimed to identify whether in addition to improvement in motor function, there were any indications that exenatide affected specific non-motor symptoms of PD compared to placebo, rather than considering the non-motor symptoms severity scale as a whole.Related StoriesCPAP treatment for sleep apnea can improve depression symptomsSocial media use and television viewing linked to rise in adolescent depressive symptomsWeighing risks and benefits of antidepressant medication for older adultsResults indicated that all measures evaluating depression improved in patients who received exenatide. The proportion of patients reporting depressive symptoms in the placebo group increased from 17% at baseline to 25% at 48 weeks, while in the exenatide group, the proportion of patients reporting depressive symptoms reduced from 23% at baseline to 6% of patients at 48 weeks. Among the other post hoc comparisons of specific non-motor symptoms, self-reported apathy and cognition also improved with exenatide.These results are of particular interest given the effects on mood appear to be independent from the previously reported beneficial effects on motor function. Furthermore, they are consistent with laboratory data indicating that exenatide has potential beneficial effects on mood in animal models.”These data should be considered as hypothesis-generating rather than formal evidence to support an effect of exenatide on mood or cognition and should not be used to influence patient treatment decisions. Nevertheless, we will consider carefully how best to capture mood severity in planned future trials of exenatide in PD,” commented Professor Foltynie.”The study of potential benefits of anti-diabetic agents that might modify disease progression in Parkinson’s is a vibrant research area. Not only are we learning about what the effects of the drugs might be in patients, but emerging parallel work in laboratories is also beginning to unravel the underlying mechanisms of action of the drugs in the brain,” added Patrik Brundin, MD, PhD, Associate Director of Research, Professor and Director of the Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, and Co-Editor-in-Chief of the Journal of Parkinson’s Disease. Source:http://www.iospress.comlast_img read more